Shows
Creep Me Out: A Podcast of True Crime, Urban Legends, & the WeirdProfile: BTKThis week Morgan tells Ari the story of the saddest, most pathetic serial killer in American History, Dennis Radar better known by his self appointed moniker, BTK.
Citations:
-Katherine Ramsland, Ph. D Confessions of a Serial Killer
-FBI Records: The Vault
https://vault.fbi.gov/dennis-rader/dennis-rader-part-01/view
-Matthew Crawford, Dennis Rader, The BTK Killer: Psychology of a Psychopath
https://thecrimewire.com/true-crime/Profile-of-a-Serial-Killer-Part-5-Dennis-Rader-The-BTK-Killer
-Michael Ruiz,Serial killer’s daughter confronts him behind bars over explosive diary entry that suggests she too was victim
...2024-10-152h 08
安全出口FMvol.318 悬案侦破录：美国连环杀手BTK，虐杀10人写信嘲讽警方，悬案30年终被抓🎙️ 主播｜老段 雨哥
在1974年到1991年这17年的时间里，有一名连环杀手用毫无人性的变态手法连续杀害了十个人，而在杀人期间杀手还喜欢穿着那些女性被害者的内衣拍照，拍完了给警方寄过去写信挑衅，只是为了嘲讽警方的无能，让自己出名。并且横行霸道30年，警察查不出线索拿他没办法。
凶手代号BTK，意为bind，Torture，kill——捆绑，折磨，杀害
这起案子差点就成了一起震惊世界的世纪悬案，直到31年后发生了一件幸运的事，警方才得以将凶手绳之以法。而这个BTK的真实身份，却让所有人都意想不到。
📌 故事梗概
00:03:42 BTK杀手来袭
00:10:49 连犯四起凶案，警方毫无头绪
00:16:25 BTK的自白信
00:22:14 OH！Death！
00:23:50 现实版哥谭恶魔BTK
00:26:08 7年之后，恶魔重现
00:27:29 玛琳之死
00:29:27 维姬受害
00:30:48 30年后悬案反转
00:31:55 两封报道钓出BTK
00:33:46 BTK“猫捉老鼠”投信
00:37:13 致命的1.44英寸软盘
00:40:00 BTK的真实身份
00:41:44 女儿大义灭亲提供DNA
00:43:11 BTK落网
00:43:58 恶魔的养成
00:49:26 剖析BTK的犯罪心理
00:55:53 十个终生监禁
💾 案件相关图像资料
杀手BTK
十位受害者
丹尼斯雷德
丹尼斯·雷德和女儿凯丽
用来绑架的绳子
南希之死
南希的画
乔瑟芬的恐怖玩偶
寄给电视台的信
BTK头版头条
BTK的杀人面具
BTK手绘画
BTK穿着受害者的衣服将自己吊起来并拍成照片
BTK杀手（2005）电影海报
📺 场景还原
🎬 制作组
监制：老段
策划：雨哥
后期：老段
设计：老段
⬆️2️⃣ 栏目介绍
楼层编号：「2F」
楼层名称：松花怪谈坊
特殊楼层设施：
收录案件：「真实性」、「世界范围」、「情感触发」、「挑战神经」
前世今生：收录的案件中，涉及相关人员（包括不限于受害者及相关家属，施暴者及相关家属，及有关人员）的人生将同样收录其中。
社会性：我们将通过「受害者」&「施暴者」&「相关社会环境」等角度出发，讲述案件背后的社会，社会下的人性。
收录频次：每月2更 / 隔周更新
层主：雨哥——如果你在此楼发现一只行动怪异，嘴瓢且呵呵呵怪笑的松鼠，恭喜你发现了ta
安全出口松花怪谈坊·往期案件回顾
往期国内外案件回顾
🟩 安全出口FM·旗下播客
晚安阁楼（毛毛睡前故事）
松鼠大侦探
高光时刻
🎧 收听方式
我们的节目，您可以在小宇宙、喜马拉雅、网易云音乐、荔枝 FM、QQ音乐、蜻蜓FM、苹果Podcast、Spotify以及其他泛用型客户端，搜索「安全出口FM」来订阅、收听。如果喜欢我们，也可以分享给你身边的朋友！
😸 交个朋友
老段：安全出口老段
雨哥：安全出口Pinecone
小编安安：@安全出口-安安 微信：anquanchukoufm
💘 合作&共创
2024-07-211h 02
安全出口FMvol.318 悬案侦破录：美国连环杀手BTK，虐杀10人写信嘲讽警方，悬案30年终被抓?️ 主播｜老段 雨哥
在1974年到1991年这17年的时间里，有一名连环杀手用毫无人性的变态手法连续杀害了十个人，而在杀人期间杀手还喜欢穿着那些女性被害者的内衣拍照，拍完了给警方寄过去写信挑衅，只是为了嘲讽警方的无能，让自己出名。并且横行霸道30年，警察查不出线索拿他没办法。
凶手代号BTK，意为bind，Torture，kill——捆绑，折磨，杀害
这起案子差点就成了一起震惊世界的世纪悬案，直到31年后发生了一件幸运的事，警方才得以将凶手绳之以法。而这个BTK的真实身份，却让所有人都意想不到。
? 故事梗概
00:03:42 BTK杀手来袭
00:10:49 连犯四起凶案，警方毫无头绪
00:16:25 BTK的自白信
00:22:14 OH！Death！
00:23:50 现实版哥谭恶魔BTK
00:26:08 7年之后，恶魔重现
00:27:29 玛琳之死
00:29:27 维姬受害
00:30:48 30年后悬案反转
00:31:55 两封报道钓出BTK
00:33:46 BTK“猫捉老鼠”投信
00:37:13 致命的1.44英寸软盘
00:40:00 BTK的真实身份
00:41:44 女儿大义灭亲提供DNA
00:43:11 BTK落网
00:43:58 恶魔的养成
00:49:26 剖析BTK的犯罪心理
00:55:53 十个终生监禁
? 案件相关图像资料
杀手BTK
十位受害者
丹尼斯雷德
丹尼斯·雷德和女儿凯丽
用来绑架的绳子
南希之死
南希的画
乔瑟芬的恐怖玩偶
寄给电视台的信
BTK头版头条
BTK的杀人面具
BTK手绘画
BTK穿着受害者的衣服将自己吊起来并拍成照片
BTK杀手（2005）电影海报
? 场景还原
? 制作组
监制：老段
策划：雨哥
后期：老段
设计：老段
⬆️2️⃣ 栏目介绍
楼层编号：「2F」
楼层名称：松花怪谈坊
特殊楼层设施：
收录案件：「真实性」、「世界范围」、「情感触发」、「挑战神经」
前世今生：收录的案件中，涉及相关人员（包括不限于受害者及相关家属，施暴者及相关家属，及有关人员）的人生将同样收录其中。
社会性：我们将通过「受害者」&「施暴者」&「相关社会环境」等角度出发，讲述案件背后的社会，社会下的人性。
收录频次：每月2更 / 隔周更新
层主：雨哥——如果你在此楼发现一只行动怪异，嘴瓢且呵呵呵怪笑的松鼠，恭喜你发现了ta
安全出口松花怪谈坊·往期案件回顾
往期国内外案件回顾
? 安全出口FM·旗下播客
晚安阁楼（毛毛睡前故事）
松鼠大侦探
高光时刻
? 收听方式
我们的节目，您可以在小宇宙、xima、某云音乐、荔枝 FM、QQ音乐、蜻蜓、苹果Podcast、Spotify以及其他泛用型客户端，搜索「安全出口FM」来订阅、收听。如果喜欢我们，也可以分享给你身边的朋友！
? 交个朋友
老段：安全出口老段
雨哥：安全出口Pinecone
小编安安：@安全出口-安安 微信：anquanchukoufm
? 合作&共创
商务合作，添加微信：duanduanduan2011（备注：品牌合作）
投稿&建议反馈，欢迎电子邮件到：anquanchukou2021@gmail.com
? 感谢各位听友
如果你喜欢我们的节目，欢迎打赏支持——爱发电，或者把我们的节目推荐给朋友～2024-07-181h 02
Y Así Les MatóEp.75 Las 10 Víctimas de BTK, pt.4Send us a Text Message. Llegamos a la ultima parte, en donde van a ver que gracias a su orgullo y su necesidad por tener fama y ser reconocido inevitablemente lo llevaron a su captura. Patreon: patreon.com/user?u=79349275Fuentes https://edition.cnn.com/2023/08/22/us/btk-serial-killer-dennis-rader-kansas-property-search/index.htmlhttps://abcnews.go.com/US/story?id=443388&page=1https://www.refinery29.com/en-us/2019/08/240763/btk-killer-letters-victims-mindhunter-season-2https://abcnews.go.com/US/btk-serial-killers-daughter-family-embracing-start-memoir/story?id=64514619https://abcnews.go.com/GMA/LegalCenter/story?id=535740&page=1https://www...2024-03-2623 minY Así Les MatóEp.75 Las 10 Víctimas de BTK, pt.1Send us a Text Message.Durante tres décadas Dennis Rader paso desapercibido por su familia, sus amigos, sus vecinos y todo el mundo que lo conoció. Daba la impresión de que era un hombre bueno pero a sus 60 años salió a la luz la verdad de quien era. Y era el asesino al que apodaron BTK, bind torture and kill, amarrar, torturar y matar. Fuentes https://www.biography.com/crime/btk-killer-dennis-rader-timelinehttps://abcnews.go.com/US/btk-serial-killers-daughter-family-embracing-start-memoir/story?id=645146192024-03-0519 min
Conexão Criminal 🇵🇹67: BTK (Apanhado 30 Anos Depois)
Um dos mais infames assassinos em série da história americana: o BTK, sigla para "Bind, Torture, Kill" (Amarrar, Torturar, Matar). Neste episódio, exploramos os horrores perpetrados por Dennis Rader, um aparentemente comum membro da comunidade de Wichita, Kansas, que escondeu uma vida dupla como predador impiedoso.
Fontes:
https://www.britannica.com/biography/Dennis-Rader
https://www.biography.com/crime/dennis-rader
https://www.crimeandinvestigation.co.uk/crime-files/dennis-rader-the-btk-killer
https://apnews.com/article/btk-serial-killer-investigation-bf9b2d69bdd3e696d7567608c1964593
https://www.biography.com/crime/btk-killer-dennis-rad...2024-02-1627 min
The Murder Book: A True Crime PodcastThe Dark Reality of BTK: An FBI Agent's Perspective Part IIIUncover the harrowing secrets of one of America's most notorious murderers. This gripping episode takes you on a chilling journey into the dark world of the infamous BTK killer. We navigate the dreadful crime scenes, analyzing the shocking methods used by the man who brought a community to its knees. Journey with us as we delve into the life scars left behind, from the victims' families to the shockwaves felt throughout the nation and John Douglass's former FBI profiler's perspective of the time this case was developing.Enter the mind of a monster as we dissect the...2023-12-041h 11The Murder Book: A True Crime PodcastThe Dark Reality of BTK: An FBI Agent's Perspective Part IHave you ever wondered about the mind of a serial killer? As we navigate this eerie journey into the psyche of the infamous Wichita murderer, we promise to shed light on the chilling life and crimes of Dennis Rader, better known as BTK. We will examine BTK's case from the perspective of former FBI profiler John Douglas to venture deep into the darkness of a killer's mind, examining the motivations and methods that powered Rader's monstrous deeds. From his first interaction with Wichita PD in 1979 to the formation of the "Ghostbusters" task force, Douglas' perspective is an insightful exploration...2023-11-211h 08
Awaiting Admission: BTK's Unconfessed Crimes | The Dennis Rader StoryWill Possible BTK Victim's Families See Justice for Murder?In a revealing discussion on the podcast "Hidden Killers," Tony Brueski seeks insights from former felony prosecutor and attorney, Eric Faddis, about the murky waters surrounding decades-old cold cases, the BTK killer, and the intricacies of investigative processes. Their conversation casts a light on the somber realities facing the families who seek closure and the complexities entangled within the legal framework.
The District Attorney's recent decision to hand over investigations to the Oklahoma State Bureau of Investigation (OSBI) regarding a case from 1976 has rekindled the public's interest. But as Faddis points out, "Sometimes those entities are not as ad...2023-09-2106 minAwaiting Admission: BTK's Unconfessed Crimes | The Dennis Rader StoryHow Many Bodies May Be Buried Under BTK's Barns?A shocking revelation has sent ripples through the cold case community: could the notorious BTK (Bind, Torture, Kill) serial killer, Dennis Rader, have had secret torture barns? Newly surfaced Polaroids and chilling sketches, indicating a possible link between the BTK killer and specific barns, have law enforcement expanding their search radius. This latest lead has not only spurred renewed investigative efforts but also reignited disagreements about the BTK’s ties to unsolved cases.
In the podcast "Hidden Killers," hosted by Tony Brueski, he delved deep into this mystery, aided by the insights of Jennifer Coffindaffer, a former FBI Spec...2023-09-1205 min
SKDDennis Rader: The BTK KillerFor three decades, the terrifying serial killer who called himself BTK ("Bind, Torture, Kill") was uncaught. First, he would cut the phone lines, and then he would get into the house somehow, waiting for his victim to come home. The killings drove Wichita's women into a frenzy, but then the murders inexplicably stopped. Police theorized that BTK could have died or have been incarcerated for some other crime or mental disease, or maybe even moved away.Then in March 2004, BTK sent a very convincing letter to the local newspaper, taking responsibility for the September 1986, unsolved death of Vicki...2023-09-032h 10
Tell me Darling8. BTK. aka DENNIS RADER
In the year 1974, the town of Wichita would fall under the shadow of a chilling phantom of terror, as a sinister game of cat and mouse unfolded before their horrified eyes. With a mind steeped in madness, meticulously selecting his victims, reveling in their suffering as he bound them, tortured them and killed them. The city shaken with fear, they would soon learn the harrowing tales of the infamous serial killer known today as BTK.
Listen on Spotify!
Find us on Instagram www.instagram.com/tellmedarling_
Sources
https://www.youtube.com/watch?v=l4s55Dna3ywhttps://murderpedia.org...2023-07-181h 06
PeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastAmit Bar-Or, MD, FRCPC - Can a Novel DMT Class Deliver Better Outcomes in MS? Considering the Potential of BTK InhibitionGo online to PeerView.com/YAJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Optimal management of multiple sclerosis (MS) requires selecting medications that safely and effectively target different aspects of pathophysiology and offer choices in administration, risk/benefit balance, and patient adherence. Bruton tyrosine kinase (BTK) inhibitors are an emerging class of disease-modifying therapies that affect processes mediated by B cells and myeloid cells, which are contributors to the inflammation and neurodegeneration that drive MS. BTK inhibitors are a novel class in MS management with four agents currently in phase 3 trials...2023-07-0643 min
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio PodcastAmit Bar-Or, MD, FRCPC - Can a Novel DMT Class Deliver Better Outcomes in MS? Considering the Potential of BTK InhibitionGo online to PeerView.com/YAJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Optimal management of multiple sclerosis (MS) requires selecting medications that safely and effectively target different aspects of pathophysiology and offer choices in administration, risk/benefit balance, and patient adherence. Bruton tyrosine kinase (BTK) inhibitors are an emerging class of disease-modifying therapies that affect processes mediated by B cells and myeloid cells, which are contributors to the inflammation and neurodegeneration that drive MS. BTK inhibitors are a novel class in MS management with four agents currently in phase 3 trials...2023-07-0643 min
PeerView Clinical Pharmacology CME/CNE/CPE VideoAmit Bar-Or, MD, FRCPC - Can a Novel DMT Class Deliver Better Outcomes in MS? Considering the Potential of BTK InhibitionGo online to PeerView.com/YAJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Optimal management of multiple sclerosis (MS) requires selecting medications that safely and effectively target different aspects of pathophysiology and offer choices in administration, risk/benefit balance, and patient adherence. Bruton tyrosine kinase (BTK) inhibitors are an emerging class of disease-modifying therapies that affect processes mediated by B cells and myeloid cells, which are contributors to the inflammation and neurodegeneration that drive MS. BTK inhibitors are a novel class in MS management with four agents currently in phase 3 trials...2023-07-0643 min
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video PodcastAmit Bar-Or, MD, FRCPC - Can a Novel DMT Class Deliver Better Outcomes in MS? Considering the Potential of BTK InhibitionGo online to PeerView.com/YAJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Optimal management of multiple sclerosis (MS) requires selecting medications that safely and effectively target different aspects of pathophysiology and offer choices in administration, risk/benefit balance, and patient adherence. Bruton tyrosine kinase (BTK) inhibitors are an emerging class of disease-modifying therapies that affect processes mediated by B cells and myeloid cells, which are contributors to the inflammation and neurodegeneration that drive MS. BTK inhibitors are a novel class in MS management with four agents currently in phase 3 trials...2023-07-0643 min
Bad Human: A Podcast about True Crime44. SERIAL KILLER: BTK (pt. 2)Send us a textWe are back for the second part of the BTK story.We pick up with victim number seven and take a deep dive into the f#$%ed up back story of this serial killer, and the monsterous crimes he committed in his own words.Our hearts and thoughts go out to all of BTK's victims, their families and those who are still impacted to this day by his chilling acts.Follow us on Instagram: https://www.instagram.com/badhumanpod/Email us with your c...2023-06-1351 minBad Human: A Podcast about True Crime43. SERIAL KILLER: BTK (pt.1)Send us a textIt was 1974 in Wichita, Kansas – kids would ride their bikes in the streets, no one locked the doors…..People felt safe, were living their best life....and had no idea a MONSTER was hiding right in plain sight. BTK would become one of the most notoriously cold blooded and twisted serial killers to ever walk the earth.HUGE trigger warning for this episode as the acts of this shit stain on society are hard for anyone to even imagine...... Follow us on Instagram: https://www.instagram.com/bad...2023-05-3042 min
The True Crime Stories PodcastThe BTK KillerWelcome to the True Crime Stories Podcast. In this gripping series, we delve deep into the chilling case of the BTK Killer. Join us as we explore the shocking crimes, the psychological profile of the killer, and the relentless pursuit of justice that finally brought him to justice.
For over three decades, the BTK Killer struck fear into the hearts of the Wichita community. Through a series of meticulously planned and brutally executed murders, he left a trail of terror and unanswered questions. Who was this mysterious predator, and what drove him to commit...2023-05-1607 minPeerView Neuroscience & Psychiatry CME/CNE/CPE Audio PodcastBenjamin M. Greenberg, MD, MHS / Jiwon Oh, MD, PhD, FRCPC - BTK Inhibition as an MS Treatment Modality: Where Do We Stand and Where Are We Headed?Go online to PeerView.com/YCW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. An evolving understanding of the role of B cells in pathophysiology of multiple sclerosis (MS) and the demonstrated success of other B cell–targeted therapies have led to great interest in the promise of Bruton tyrosine kinase (BTK) inhibitors as a novel MS treatment class. Compared with anti-CD20 monoclonal antibodies, BTK inhibitors are understood to offer the promise of greater selectivity that leaves healthy B cells intact, as well as the ability to cross the blood–brain barrier and...2023-03-2945 minPeerView Neuroscience & Psychiatry CME/CNE/CPE Video PodcastBenjamin M. Greenberg, MD, MHS / Jiwon Oh, MD, PhD, FRCPC - BTK Inhibition as an MS Treatment Modality: Where Do We Stand and Where Are We Headed?Go online to PeerView.com/YCW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. An evolving understanding of the role of B cells in pathophysiology of multiple sclerosis (MS) and the demonstrated success of other B cell–targeted therapies have led to great interest in the promise of Bruton tyrosine kinase (BTK) inhibitors as a novel MS treatment class. Compared with anti-CD20 monoclonal antibodies, BTK inhibitors are understood to offer the promise of greater selectivity that leaves healthy B cells intact, as well as the ability to cross the blood–brain barrier and...2023-03-2945 minPeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastBenjamin M. Greenberg, MD, MHS / Jiwon Oh, MD, PhD, FRCPC - BTK Inhibition as an MS Treatment Modality: Where Do We Stand and Where Are We Headed?Go online to PeerView.com/YCW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. An evolving understanding of the role of B cells in pathophysiology of multiple sclerosis (MS) and the demonstrated success of other B cell–targeted therapies have led to great interest in the promise of Bruton tyrosine kinase (BTK) inhibitors as a novel MS treatment class. Compared with anti-CD20 monoclonal antibodies, BTK inhibitors are understood to offer the promise of greater selectivity that leaves healthy B cells intact, as well as the ability to cross the blood–brain barrier and...2023-03-2945 minPeerView Clinical Pharmacology CME/CNE/CPE VideoBenjamin M. Greenberg, MD, MHS / Jiwon Oh, MD, PhD, FRCPC - BTK Inhibition as an MS Treatment Modality: Where Do We Stand and Where Are We Headed?Go online to PeerView.com/YCW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. An evolving understanding of the role of B cells in pathophysiology of multiple sclerosis (MS) and the demonstrated success of other B cell–targeted therapies have led to great interest in the promise of Bruton tyrosine kinase (BTK) inhibitors as a novel MS treatment class. Compared with anti-CD20 monoclonal antibodies, BTK inhibitors are understood to offer the promise of greater selectivity that leaves healthy B cells intact, as well as the ability to cross the blood–brain barrier and...2023-03-2945 minPeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCLGo online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case...2022-08-101h 09
PeerView Immunology & Transplantation CME/CNE/CPE Audio PodcastDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCLGo online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case...2022-08-101h 09
PeerView Internal Medicine CME/CNE/CPE Video PodcastDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCLGo online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case...2022-08-101h 09
PeerView Immunology & Transplantation CME/CNE/CPE Video PodcastDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCLGo online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case...2022-08-101h 09
PeerView Oncology & Hematology CME/CNE/CPE Audio PodcastDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCLGo online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case...2022-08-101h 09
PeerView Internal Medicine CME/CNE/CPE Audio PodcastDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCLGo online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case...2022-08-101h 09
PeerView Heart, Lung & Blood CME/CNE/CPE Audio PodcastDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCLGo online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case...2022-08-101h 09PeerView Clinical Pharmacology CME/CNE/CPE VideoDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCLGo online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case...2022-08-101h 09
PeerView Oncology & Hematology CME/CNE/CPE Video PodcastDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCLGo online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case...2022-08-101h 09
PeerView Heart, Lung & Blood CME/CNE/CPE Video PodcastDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCLGo online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case...2022-08-101h 09
CCO Oncology PodcastExpert Answers to Key Questions on Current and Emerging BTK Inhibitor Therapies for CLL and MCLIn this episode, Jeff P. Sharman, MD; Matthew S. Davids, MD, MMSc; and Anthony Mato, MD, MSCE, answer questions from a live CCO webinar on current best practices and emerging strategies in BTK inhibitor therapy for patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), with questions including:For patients with CLL, when should acalabrutinib-, ibrutinib-, or venetoclax-based regimens be considered?What is the optimal therapy for a patient with del(17p) CLL?When should an anti-CD20 antibody be added to BTK inhibitor therapy for patients with CLL?What are best practices in the use of B...2022-03-3128 min
RicardoNoveBTK Profile - A máscara da maldade⏳BTK Profile - A máscara da maldade
✍️ Roy Wenzl, Tim Potter, Hurst Laviana e L. Kelly
Ao longo de três décadas, um monstro aterrorizou os moradores de Wichita, Kansas. Um assassino em série que amarrava, torturava e matava mulheres, homens e crianças, iludiu a polícia por anos a fio enquanto se vangloriava de suas terríveis façanhas para a mídia. A nação ficou chocada quando os crimes de BTK ― a sigla para os termos em inglês bind, torture, kill, que eram sua assinatura criminosa ― foram enfim associados a Dennis Rader, um vizinho amigável, m...2022-03-2805 minPeerView Internal Medicine CME/CNE/CPE Audio PodcastAnthony R. Mato - The Rising Tide of Novel BTK Inhibitors: Case-Based Guidance on Overcoming Intolerance, Resistance, and Other Clinical Challenges in B-Cell CancersGo online to PeerView.com/CZP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Covalent BTK inhibitors have transformed the care of B-cell cancers such as CLL/SLL and MCL, but challenges to optimal care remain. How well do you understand the barriers to consistent, efficacious treatment with BTK-based treatment and what that means for treatment planning across multiple lines of therapy? During this activity, experts will tackle these questions and demonstrate how to strategically plan for and implement management protocols that address clinical problems such as BTK inhibitor resistance and intolerance...2022-03-171h 00PeerView Oncology & Hematology CME/CNE/CPE Audio PodcastAnthony R. Mato - The Rising Tide of Novel BTK Inhibitors: Case-Based Guidance on Overcoming Intolerance, Resistance, and Other Clinical Challenges in B-Cell CancersGo online to PeerView.com/CZP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Covalent BTK inhibitors have transformed the care of B-cell cancers such as CLL/SLL and MCL, but challenges to optimal care remain. How well do you understand the barriers to consistent, efficacious treatment with BTK-based treatment and what that means for treatment planning across multiple lines of therapy? During this activity, experts will tackle these questions and demonstrate how to strategically plan for and implement management protocols that address clinical problems such as BTK inhibitor resistance and intolerance...2022-03-171h 00PeerView Oncology & Hematology CME/CNE/CPE Video PodcastAnthony R. Mato - The Rising Tide of Novel BTK Inhibitors: Case-Based Guidance on Overcoming Intolerance, Resistance, and Other Clinical Challenges in B-Cell CancersGo online to PeerView.com/CZP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Covalent BTK inhibitors have transformed the care of B-cell cancers such as CLL/SLL and MCL, but challenges to optimal care remain. How well do you understand the barriers to consistent, efficacious treatment with BTK-based treatment and what that means for treatment planning across multiple lines of therapy? During this activity, experts will tackle these questions and demonstrate how to strategically plan for and implement management protocols that address clinical problems such as BTK inhibitor resistance and intolerance...2022-03-171h 00PeerView Internal Medicine CME/CNE/CPE Video PodcastAnthony R. Mato - The Rising Tide of Novel BTK Inhibitors: Case-Based Guidance on Overcoming Intolerance, Resistance, and Other Clinical Challenges in B-Cell CancersGo online to PeerView.com/CZP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Covalent BTK inhibitors have transformed the care of B-cell cancers such as CLL/SLL and MCL, but challenges to optimal care remain. How well do you understand the barriers to consistent, efficacious treatment with BTK-based treatment and what that means for treatment planning across multiple lines of therapy? During this activity, experts will tackle these questions and demonstrate how to strategically plan for and implement management protocols that address clinical problems such as BTK inhibitor resistance and intolerance...2022-03-171h 00PeerView Clinical Pharmacology CME/CNE/CPE VideoAnthony R. Mato - The Rising Tide of Novel BTK Inhibitors: Case-Based Guidance on Overcoming Intolerance, Resistance, and Other Clinical Challenges in B-Cell CancersGo online to PeerView.com/CZP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Covalent BTK inhibitors have transformed the care of B-cell cancers such as CLL/SLL and MCL, but challenges to optimal care remain. How well do you understand the barriers to consistent, efficacious treatment with BTK-based treatment and what that means for treatment planning across multiple lines of therapy? During this activity, experts will tackle these questions and demonstrate how to strategically plan for and implement management protocols that address clinical problems such as BTK inhibitor resistance and intolerance...2022-03-171h 00PeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastAnthony R. Mato - The Rising Tide of Novel BTK Inhibitors: Case-Based Guidance on Overcoming Intolerance, Resistance, and Other Clinical Challenges in B-Cell CancersGo online to PeerView.com/CZP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Covalent BTK inhibitors have transformed the care of B-cell cancers such as CLL/SLL and MCL, but challenges to optimal care remain. How well do you understand the barriers to consistent, efficacious treatment with BTK-based treatment and what that means for treatment planning across multiple lines of therapy? During this activity, experts will tackle these questions and demonstrate how to strategically plan for and implement management protocols that address clinical problems such as BTK inhibitor resistance and intolerance...2022-03-171h 00PeerView Heart, Lung & Blood CME/CNE/CPE Audio PodcastJohn C. Byrd, MD - Customizing Care in CLL With BTK Inhibitors: Evidence and Applications for Therapy Selection, Sequencing, and Safety ManagementGo online to PeerView.com/HZU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView ”Clinical Consults” offers a window into how experts customize BTK inhibitor therapy to achieve optimal CLL care—and represents a timely and relevant guide to using potent therapies that have transformed patient management. Throughout, the experts will debate real-world clinical scenarios (supported by mini-lectures) designed to explore the use of first- and second-generation BTK inhibitors and address issues such as: selectivity and safety differences among BTK inhibitors; choosing a BTK option in treatment-naïve CLL; using phase 3...2022-01-211h 25PeerView Heart, Lung & Blood CME/CNE/CPE Video PodcastJohn C. Byrd, MD - Customizing Care in CLL With BTK Inhibitors: Evidence and Applications for Therapy Selection, Sequencing, and Safety ManagementGo online to PeerView.com/HZU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView ”Clinical Consults” offers a window into how experts customize BTK inhibitor therapy to achieve optimal CLL care—and represents a timely and relevant guide to using potent therapies that have transformed patient management. Throughout, the experts will debate real-world clinical scenarios (supported by mini-lectures) designed to explore the use of first- and second-generation BTK inhibitors and address issues such as: selectivity and safety differences among BTK inhibitors; choosing a BTK option in treatment-naïve CLL; using phase 3...2022-01-211h 25
PeerView Family Medicine & General Practice CME/CNE/CPE Video PodcastJohn C. Byrd, MD - Customizing Care in CLL With BTK Inhibitors: Evidence and Applications for Therapy Selection, Sequencing, and Safety ManagementGo online to PeerView.com/HZU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView ”Clinical Consults” offers a window into how experts customize BTK inhibitor therapy to achieve optimal CLL care—and represents a timely and relevant guide to using potent therapies that have transformed patient management. Throughout, the experts will debate real-world clinical scenarios (supported by mini-lectures) designed to explore the use of first- and second-generation BTK inhibitors and address issues such as: selectivity and safety differences among BTK inhibitors; choosing a BTK option in treatment-naïve CLL; using phase 3...2022-01-211h 25PeerView Oncology & Hematology CME/CNE/CPE Video PodcastJohn C. Byrd, MD - Customizing Care in CLL With BTK Inhibitors: Evidence and Applications for Therapy Selection, Sequencing, and Safety ManagementGo online to PeerView.com/HZU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView ”Clinical Consults” offers a window into how experts customize BTK inhibitor therapy to achieve optimal CLL care—and represents a timely and relevant guide to using potent therapies that have transformed patient management. Throughout, the experts will debate real-world clinical scenarios (supported by mini-lectures) designed to explore the use of first- and second-generation BTK inhibitors and address issues such as: selectivity and safety differences among BTK inhibitors; choosing a BTK option in treatment-naïve CLL; using phase 3...2022-01-211h 25PeerView Internal Medicine CME/CNE/CPE Video PodcastJohn C. Byrd, MD - Customizing Care in CLL With BTK Inhibitors: Evidence and Applications for Therapy Selection, Sequencing, and Safety ManagementGo online to PeerView.com/HZU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView ”Clinical Consults” offers a window into how experts customize BTK inhibitor therapy to achieve optimal CLL care—and represents a timely and relevant guide to using potent therapies that have transformed patient management. Throughout, the experts will debate real-world clinical scenarios (supported by mini-lectures) designed to explore the use of first- and second-generation BTK inhibitors and address issues such as: selectivity and safety differences among BTK inhibitors; choosing a BTK option in treatment-naïve CLL; using phase 3...2022-01-211h 25
PeerView Family Medicine & General Practice CME/CNE/CPE Audio PodcastJohn C. Byrd, MD - Customizing Care in CLL With BTK Inhibitors: Evidence and Applications for Therapy Selection, Sequencing, and Safety ManagementGo online to PeerView.com/HZU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView ”Clinical Consults” offers a window into how experts customize BTK inhibitor therapy to achieve optimal CLL care—and represents a timely and relevant guide to using potent therapies that have transformed patient management. Throughout, the experts will debate real-world clinical scenarios (supported by mini-lectures) designed to explore the use of first- and second-generation BTK inhibitors and address issues such as: selectivity and safety differences among BTK inhibitors; choosing a BTK option in treatment-naïve CLL; using phase 3...2022-01-211h 25PeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastJohn C. Byrd, MD - Customizing Care in CLL With BTK Inhibitors: Evidence and Applications for Therapy Selection, Sequencing, and Safety ManagementGo online to PeerView.com/HZU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView ”Clinical Consults” offers a window into how experts customize BTK inhibitor therapy to achieve optimal CLL care—and represents a timely and relevant guide to using potent therapies that have transformed patient management. Throughout, the experts will debate real-world clinical scenarios (supported by mini-lectures) designed to explore the use of first- and second-generation BTK inhibitors and address issues such as: selectivity and safety differences among BTK inhibitors; choosing a BTK option in treatment-naïve CLL; using phase 3...2022-01-211h 25PeerView Clinical Pharmacology CME/CNE/CPE VideoJohn C. Byrd, MD - Customizing Care in CLL With BTK Inhibitors: Evidence and Applications for Therapy Selection, Sequencing, and Safety ManagementGo online to PeerView.com/HZU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView ”Clinical Consults” offers a window into how experts customize BTK inhibitor therapy to achieve optimal CLL care—and represents a timely and relevant guide to using potent therapies that have transformed patient management. Throughout, the experts will debate real-world clinical scenarios (supported by mini-lectures) designed to explore the use of first- and second-generation BTK inhibitors and address issues such as: selectivity and safety differences among BTK inhibitors; choosing a BTK option in treatment-naïve CLL; using phase 3...2022-01-211h 25PeerView Internal Medicine CME/CNE/CPE Audio PodcastJohn C. Byrd, MD - Customizing Care in CLL With BTK Inhibitors: Evidence and Applications for Therapy Selection, Sequencing, and Safety ManagementGo online to PeerView.com/HZU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView ”Clinical Consults” offers a window into how experts customize BTK inhibitor therapy to achieve optimal CLL care—and represents a timely and relevant guide to using potent therapies that have transformed patient management. Throughout, the experts will debate real-world clinical scenarios (supported by mini-lectures) designed to explore the use of first- and second-generation BTK inhibitors and address issues such as: selectivity and safety differences among BTK inhibitors; choosing a BTK option in treatment-naïve CLL; using phase 3...2022-01-211h 25PeerView Oncology & Hematology CME/CNE/CPE Audio PodcastJohn C. Byrd, MD - Customizing Care in CLL With BTK Inhibitors: Evidence and Applications for Therapy Selection, Sequencing, and Safety ManagementGo online to PeerView.com/HZU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView ”Clinical Consults” offers a window into how experts customize BTK inhibitor therapy to achieve optimal CLL care—and represents a timely and relevant guide to using potent therapies that have transformed patient management. Throughout, the experts will debate real-world clinical scenarios (supported by mini-lectures) designed to explore the use of first- and second-generation BTK inhibitors and address issues such as: selectivity and safety differences among BTK inhibitors; choosing a BTK option in treatment-naïve CLL; using phase 3...2022-01-211h 25
Karat Juice PodcastEp. 47 BTK Serial Killer, Dennis Rader: "I'm a Good Person who did BAD THINGS"!BTK killer Dennis Rader has a take on himself ... he's both a monster and a good guy. Rader appears on a new, Dick Wolf documentary on A&E -- "BTK: Confession of a Serial Killer" -- in which he chats with a psychologist about his killing spree and the motivations behind it. The self-proclaimed BTK killer says he is indeed a "monster," but also a "good person who did some bad things." BTK, by the way, is short for bind, torture, kill. As you know, Rader, a church leader, pled guilty in 2005 to killing 10 people to satisfy his sexual...2022-01-1253 min
Dark. Damned. & Disturbed.54. SERIAL KILLER: Dennis Rader aka BTKIt’s an Emily Episode! Today Emily’s covering BTK. This case is absolutely disturbing. Emily gives him a lovely nickname which we think describes him best. We hope you guys enjoy this episode and have a wonderful holiday season! https://www.oxygen.com/snapped/crime-time/crime-scene-photos-btk-killer-murdershttps://www.dailymail.co.uk/news/article-6669831/Son-BTK-killers-victims-tells-family-strangled-bound-age-15.htmlhttps://murderpedia.org/male.R/r/rader-dennis-kathryn-bright.htmhttps://www.cnn.com/2005/LAW/03/01/btk.relford/index.htmlhttps://survivingbtk.weebly.com/nancy-fox.htmlhttps://murderpedia.org/male.R/r/rader-dennis-marine-hedge.htmhttps://www.karisable.com/skazbtkvw.htmhttps://murderpedia.org/male.R/r/rader-dennis-dolores-davis.htmhttps://www.biography.com/news/btk-killer-dennis-rader-timelinehttp://www.crim...2021-12-2554 minPeerView Clinical Pharmacology CME/CNE/CPE VideoNicole Lamanna, MD / Jennifer Woyach, MD - Seizing the Day With BTK Inhibitors in CLL: Evidence-Informed Therapy Selection, Safety, and Sequential CareGo online to PeerView.com/QZB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in chronic lymphocytic leukemia (CLL) management discuss the current evidence and clinical data supporting the use of first- and second-generation BTK inhibitors in CLL. The experts use this evidence to build a series of case scenarios designed to illustrate how professionals can seize the opportunity to personalize BTK inhibitor usage based on changing circumstances, patient features, and safety considerations. Upon completion of this accredited CE activity, participants should be better able to: Review...2021-10-201h 29PeerView Oncology & Hematology CME/CNE/CPE Video PodcastNicole Lamanna, MD / Jennifer Woyach, MD - Seizing the Day With BTK Inhibitors in CLL: Evidence-Informed Therapy Selection, Safety, and Sequential CareGo online to PeerView.com/QZB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in chronic lymphocytic leukemia (CLL) management discuss the current evidence and clinical data supporting the use of first- and second-generation BTK inhibitors in CLL. The experts use this evidence to build a series of case scenarios designed to illustrate how professionals can seize the opportunity to personalize BTK inhibitor usage based on changing circumstances, patient features, and safety considerations. Upon completion of this accredited CE activity, participants should be better able to: Review...2021-10-201h 29PeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastNicole Lamanna, MD / Jennifer Woyach, MD - Seizing the Day With BTK Inhibitors in CLL: Evidence-Informed Therapy Selection, Safety, and Sequential CareGo online to PeerView.com/QZB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in chronic lymphocytic leukemia (CLL) management discuss the current evidence and clinical data supporting the use of first- and second-generation BTK inhibitors in CLL. The experts use this evidence to build a series of case scenarios designed to illustrate how professionals can seize the opportunity to personalize BTK inhibitor usage based on changing circumstances, patient features, and safety considerations. Upon completion of this accredited CE activity, participants should be better able to: Review...2021-10-201h 28PeerView Internal Medicine CME/CNE/CPE Video PodcastNicole Lamanna, MD / Jennifer Woyach, MD - Seizing the Day With BTK Inhibitors in CLL: Evidence-Informed Therapy Selection, Safety, and Sequential CareGo online to PeerView.com/QZB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in chronic lymphocytic leukemia (CLL) management discuss the current evidence and clinical data supporting the use of first- and second-generation BTK inhibitors in CLL. The experts use this evidence to build a series of case scenarios designed to illustrate how professionals can seize the opportunity to personalize BTK inhibitor usage based on changing circumstances, patient features, and safety considerations. Upon completion of this accredited CE activity, participants should be better able to: Review...2021-10-201h 29PeerView Internal Medicine CME/CNE/CPE Audio PodcastNicole Lamanna, MD / Jennifer Woyach, MD - Seizing the Day With BTK Inhibitors in CLL: Evidence-Informed Therapy Selection, Safety, and Sequential CareGo online to PeerView.com/QZB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in chronic lymphocytic leukemia (CLL) management discuss the current evidence and clinical data supporting the use of first- and second-generation BTK inhibitors in CLL. The experts use this evidence to build a series of case scenarios designed to illustrate how professionals can seize the opportunity to personalize BTK inhibitor usage based on changing circumstances, patient features, and safety considerations. Upon completion of this accredited CE activity, participants should be better able to: Review...2021-10-201h 28PeerView Oncology & Hematology CME/CNE/CPE Audio PodcastNicole Lamanna, MD / Jennifer Woyach, MD - Seizing the Day With BTK Inhibitors in CLL: Evidence-Informed Therapy Selection, Safety, and Sequential CareGo online to PeerView.com/QZB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in chronic lymphocytic leukemia (CLL) management discuss the current evidence and clinical data supporting the use of first- and second-generation BTK inhibitors in CLL. The experts use this evidence to build a series of case scenarios designed to illustrate how professionals can seize the opportunity to personalize BTK inhibitor usage based on changing circumstances, patient features, and safety considerations. Upon completion of this accredited CE activity, participants should be better able to: Review...2021-10-201h 28PeerView Oncology & Hematology CME/CNE/CPE Video PodcastAnthony R. Mato, MD, MSCE - The Next Building Block for B-Cell Cancer Care: Exploring Personalized Treatment With Emerging BTK Inhibitor Options in CLL/SLL and MCLGo online to PeerView.com/QXD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite the success of BTK inhibitor therapy in B-cell malignancies, therapeutic resistance and intolerance represent barriers to effective, sustained anticancer therapy. What can clinicians do in the face of this challenge? In this case-based “Clinical Consults” discussion, a panel of leading experts meet this challenge head on and provide guidance on how to plan for and proactively capture the emergence of BTK resistance and intolerance, address the medical challenges of selecting effective sequential therapy, and prepare for the emer...2021-10-121h 02PeerView Heart, Lung & Blood CME/CNE/CPE Video PodcastAnthony R. Mato, MD, MSCE - The Next Building Block for B-Cell Cancer Care: Exploring Personalized Treatment With Emerging BTK Inhibitor Options in CLL/SLL and MCLGo online to PeerView.com/QXD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite the success of BTK inhibitor therapy in B-cell malignancies, therapeutic resistance and intolerance represent barriers to effective, sustained anticancer therapy. What can clinicians do in the face of this challenge? In this case-based “Clinical Consults” discussion, a panel of leading experts meet this challenge head on and provide guidance on how to plan for and proactively capture the emergence of BTK resistance and intolerance, address the medical challenges of selecting effective sequential therapy, and prepare for the emer...2021-10-121h 02PeerView Internal Medicine CME/CNE/CPE Audio PodcastAnthony R. Mato, MD, MSCE - The Next Building Block for B-Cell Cancer Care: Exploring Personalized Treatment With Emerging BTK Inhibitor Options in CLL/SLL and MCLGo online to PeerView.com/QXD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite the success of BTK inhibitor therapy in B-cell malignancies, therapeutic resistance and intolerance represent barriers to effective, sustained anticancer therapy. What can clinicians do in the face of this challenge? In this case-based “Clinical Consults” discussion, a panel of leading experts meet this challenge head on and provide guidance on how to plan for and proactively capture the emergence of BTK resistance and intolerance, address the medical challenges of selecting effective sequential therapy, and prepare for the emer...2021-10-121h 02PeerView Oncology & Hematology CME/CNE/CPE Audio PodcastAnthony R. Mato, MD, MSCE - The Next Building Block for B-Cell Cancer Care: Exploring Personalized Treatment With Emerging BTK Inhibitor Options in CLL/SLL and MCLGo online to PeerView.com/QXD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite the success of BTK inhibitor therapy in B-cell malignancies, therapeutic resistance and intolerance represent barriers to effective, sustained anticancer therapy. What can clinicians do in the face of this challenge? In this case-based “Clinical Consults” discussion, a panel of leading experts meet this challenge head on and provide guidance on how to plan for and proactively capture the emergence of BTK resistance and intolerance, address the medical challenges of selecting effective sequential therapy, and prepare for the emer...2021-10-121h 02PeerView Heart, Lung & Blood CME/CNE/CPE Audio PodcastAnthony R. Mato, MD, MSCE - The Next Building Block for B-Cell Cancer Care: Exploring Personalized Treatment With Emerging BTK Inhibitor Options in CLL/SLL and MCLGo online to PeerView.com/QXD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite the success of BTK inhibitor therapy in B-cell malignancies, therapeutic resistance and intolerance represent barriers to effective, sustained anticancer therapy. What can clinicians do in the face of this challenge? In this case-based “Clinical Consults” discussion, a panel of leading experts meet this challenge head on and provide guidance on how to plan for and proactively capture the emergence of BTK resistance and intolerance, address the medical challenges of selecting effective sequential therapy, and prepare for the emer...2021-10-121h 02PeerView Clinical Pharmacology CME/CNE/CPE VideoAnthony R. Mato, MD, MSCE - The Next Building Block for B-Cell Cancer Care: Exploring Personalized Treatment With Emerging BTK Inhibitor Options in CLL/SLL and MCLGo online to PeerView.com/QXD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite the success of BTK inhibitor therapy in B-cell malignancies, therapeutic resistance and intolerance represent barriers to effective, sustained anticancer therapy. What can clinicians do in the face of this challenge? In this case-based “Clinical Consults” discussion, a panel of leading experts meet this challenge head on and provide guidance on how to plan for and proactively capture the emergence of BTK resistance and intolerance, address the medical challenges of selecting effective sequential therapy, and prepare for the emer...2021-10-121h 02PeerView Internal Medicine CME/CNE/CPE Video PodcastAnthony R. Mato, MD, MSCE - The Next Building Block for B-Cell Cancer Care: Exploring Personalized Treatment With Emerging BTK Inhibitor Options in CLL/SLL and MCLGo online to PeerView.com/QXD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite the success of BTK inhibitor therapy in B-cell malignancies, therapeutic resistance and intolerance represent barriers to effective, sustained anticancer therapy. What can clinicians do in the face of this challenge? In this case-based “Clinical Consults” discussion, a panel of leading experts meet this challenge head on and provide guidance on how to plan for and proactively capture the emergence of BTK resistance and intolerance, address the medical challenges of selecting effective sequential therapy, and prepare for the emer...2021-10-121h 02PeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastAnthony R. Mato, MD, MSCE - The Next Building Block for B-Cell Cancer Care: Exploring Personalized Treatment With Emerging BTK Inhibitor Options in CLL/SLL and MCLGo online to PeerView.com/QXD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite the success of BTK inhibitor therapy in B-cell malignancies, therapeutic resistance and intolerance represent barriers to effective, sustained anticancer therapy. What can clinicians do in the face of this challenge? In this case-based “Clinical Consults” discussion, a panel of leading experts meet this challenge head on and provide guidance on how to plan for and proactively capture the emergence of BTK resistance and intolerance, address the medical challenges of selecting effective sequential therapy, and prepare for the emer...2021-10-121h 02
Podize Podcast#020 - TUDO SOBRE INVESTIMENTO | ANGELO E DIEGO - BTK - Podize PodcastNo episódio desta semana temos nossos parceiros da BTK Holding, Angelo Homen e Diego Costa para trocar uma ideia sobre a empresa e sobre o futuro de investimentos! Chega acompanhar essa conversa que a gente aprendeu muita coisa!!
CONVIDADO:
https://www.instagram.com/angelohomen/
https://www.instagram.com/diegoocostt/
https://www.instagram.com/btk_holding/
https://www.instagram.com/btk_a.intelligence/
https://www.instagram.com/btk_educacional/
--------------------------------------------------------
2021-10-061h 45
Homicide Worldwide PodcastDennis Lynn Radar "BTK Killer" Ep 033 Part 2Dennis Lynn Rader (born March 9, 1945) is an American serial killer known as BTK (an abbreviation he gave himself, for "bind, torture, kill"), the BTK Strangler or the BTK Killer. Between 1974 and 1991, Rader killed ten people in Wichita and Park City, Kansas, and sent taunting letters to police and newspapers describing the details of his crimes. After a decade-long hiatus, Rader resumed sending letters in 2004, leading to his 2005 arrest and subsequent guilty plea. He is serving ten consecutive life sentences at El Dorado Correctional Facility in Prospect Township...2021-08-112h 36